Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.03 USD
Change Today -0.0021 / -5.83%
Volume 1.2M
As of 5:20 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Mark W. Frohlich M.D.

Former Chief Medical Officer and Executive Vice President of Research & Development, Dendreon Corp.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 2 different industries.

As of Fiscal Year 2013


Dr. Mark W. Frohlich, M.D. has been an Executive Vice President of Research & Development at Juno Therapeutics Inc. since February 2014. Dr. Frohlich has more than two decades of experience in the field of immuno-oncology. Dr. Frohlich served as the Chief Medical Officer of Dendreon Corp. since January 2008 until February 1, 2014 and as its Executive Vice President of Research and Development from March 2011 to February 1, 2014, where he led teams responsible for the ...

Read Full Background

Corporate Headquarters*

1301 2nd Avenue
Seattle, Washington 98101

United States

Phone: 206-256-4545
Fax: 206-256-0571

Board Members Memberships*

There is no Board Members Memberships data available.


Yale University
Harvard Medical School
Post-Doctoral Training
University of California-San Francisco

Other Affiliations*

Annual Compensation*

Total Annual Compensation$566,667

Stock Options*

Restricted Stock Awards$1,375,000

Total Compensation*

Total Annual Cash Compensation$674,667
Total Short Term Compensation$566,667
Other Long Term Compensation$1,375,000
Total Calculated Compensation$2,049,667
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DNDNQ:US $0.03 USD -0.0021


There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DENDREON CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at